Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.56 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.56 |
| ▸ | BRAF | P15056 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 6/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690536 | 0.82 | MAP2K7 (0.69) | KDRTNNI3KMAPK14BRAFEGFR | |
| SCHEMBL8219021 | 0.75 | NPC1 (0.58) | KDRTNNI3KEGFRMAP2K7ABL1 | |
| SCHEMBL12262588 | 0.75 | EGFR (0.51) | KDRTNNI3KMAPK14BRAFEGFR | |
| SCHEMBL12262347 | 0.74 | MAP2K7 (0.57) | KDRTNNI3KEGFRERBB2MAP2K7 | |
| SCHEMBL691113 | 0.74 | EGFR (0.67) | EGFRERBB2MAP2K7JAK3BTK | |
| SCHEMBL22528777 | 0.73 | CSF1R (0.65) | KDRTNNI3KMAPK14BRAFEGFR | |
| SCHEMBL13148414 | 0.73 | KDR (0.53) | KDRTNNI3KMAPK14BRAFMAP2K7 | |
| SCHEMBL692807 | 0.72 | EGFR (0.68) | EGFRERBB2MAP2K7JAK3BTK | |
| SCHEMBL1897213 | 0.72 | KDR (0.80) | KDRTNNI3KMAPK14BRAF | |
| SCHEMBL22592397 | 0.71 | KDR (0.49) | KDRTNNI3KMAPK14BRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885TNNI3K 3700/4885MAPK14 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.